In contrast to other forms of radiation therapy for wet AMD, NeoVista's approach delivers the peak dose of energy directly to the lesion without damaging the normal retinal vasculature. Utilizing strontium 90, the focused energy is delivered to a target area up to 3 mm in depth and up to 5.4 mm in diameter. Importantly for patients, the systemic exposure to radiation is minimal, as the effective dose to the entire body from NeoVista's epiretinal device is less than that from a typical chest x-ray.
With the continued promise of these Phase II trial results, NeoVista continues to enroll patients in the company's pivotal trial, CABERNET. CABERNET is a multicenter, randomized, controlled study that will enroll 450 subjects at 45 sites worldwide, evaluating the safety and efficacy of NeoVista's epiretinal brachytherapy delivered concomitantly with the FDA-approved anti-VEGF therapy Lucentis(R) (ranibizumab) versus Lucentis alone.
"The Royal National Institute of Blind People (RNIB) welcomes the results of the Phase II study for NeoVista's therapy, which may increase the treatment options for people with wet AMD," said Barbara McLaughlan, RNIB Campaigns Manager for Eye Health and Social Care. "It is our hope that these results are confirmed in the Phase III trial that is now being conducted as wet AMD is the leading cause of sight loss in the UK and patients need a variety of choices of proven treatments to be available in the National Health Service so they can choose the therapy that's best for them."
About NeoVista, Inc.
NeoVista, Inc. is a privately held development-stage medical device
company based in Fremont, California. NeoVista's epiretinal beta radiation
therapy is currently being studied in a definitive Phase III clinical study
to support eventual filing for regu
|SOURCE NeoVista, Inc.|
Copyright©2008 PR Newswire.
All rights reserved